193 related articles for article (PubMed ID: 15023936)
1. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
3. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
4. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Azizi M; Blanchard A; Charbit B; Wuerzner G; Peyrard S; Ezan E; Funck-Brentano C; Ménard J
Hypertension; 2013 Jun; 61(6):1239-45. PubMed ID: 23608658
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
9. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
11. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
[TBL] [Abstract][Full Text] [Related]
12. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Fridman KU; Elmfeldt D; Wysocki M; Friberg PR; Andersson OK
Blood Press; 2002; 11(4):244-52. PubMed ID: 12361194
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
Tsuruoka S; Wakaumi M; Ioka T; Yamamoto H; Ando H; Sugimoto K; Fujimura A
Br J Clin Pharmacol; 2005 Aug; 60(2):204-7. PubMed ID: 16042674
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation.
Siragy HM; Xue C; Abadir P; Carey RM
Hypertension; 2005 Jan; 45(1):133-7. PubMed ID: 15534073
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
17. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.
Azizi M; Guyene TT; Chatellier G; Ménard J
Clin Exp Hypertens; 1997; 19(5-6):937-51. PubMed ID: 9247766
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
